Pricing Log in Create free account

DiaMedica Therapeutics, Inc. (DMAC) vs MiMedx Group, Inc (MDXG)

DiaMedica Therapeutics, Inc. and MiMedx Group, Inc are both Biotechnology companies. DiaMedica Therapeutics, Inc. and MiMedx Group, Inc are of similar size ($487.5M and $478.6M). DiaMedica Therapeutics, Inc. has the higher net margin (0.00% vs −6.32%) and the higher return on invested capital (0.00% vs −17.4%). Across the 13 metrics below, MiMedx Group, Inc leads on 9 and DiaMedica Therapeutics, Inc. on 4.

Valuation

Metric DMAC MDXG Biotechnology median
P/E n/m n/m 10.60
P/S n/m 1.59 9.40
P/B 13.30 2.29 2.13
Price to free cash flow n/m 25.38 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 1.25 9.02
Earnings yield (7.61%) (3.91%) (32.88%)
Free cash flow yield (6.19%) 3.94% (23.13%)

Profitability

Metric DMAC MDXG Biotechnology median
Gross margin 0.00% 77.29% 68.51%
Operating margin 0.00% (8.28%) 0.00%
Net margin 0.00% (6.32%) 0.00%
Free cash flow margin 0.00% 6.26% 0.00%
Return on equity (114.62%) (8.53%) (51.96%)
Return on assets (98.18%) (6.58%) (46.06%)
Return on invested capital 0.00% (17.40%) 0.00%

Growth

Metric DMAC MDXG Biotechnology median
Revenue growth (TTM) — (22.80%) 6.76%
EPS growth (last fiscal year) (16.67%) 14.29% 29.88%
Revenue growth, 5-year CAGR — 11.02% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC MDXG Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.72 4.35 4.97
Net debt to EBITDA 1.70 (1.88) 1.01

Dividend

Metric DMAC MDXG Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DMAC MDXG Biotechnology median
Market cap 487.49m 478.63m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack